Danesi, Romano

Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial

Cremolini, C., Rossini, D., Dell’Aquila, E., Lonardi, S., Conca, E., Del Re, M., Busico, A., Pietrantonio, F., Danesi, R., Aprile, G., et al. (2019) · JAMA Oncology

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 424

Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy

Minari, R., Bordi, P., Del Re, M., Facchinetti, F., Mazzoni, F., Barbieri, F., Camerini, A., Comin, C. E., Gnetti, L., Azzoni, C., et al. (2018) · Lung Cancer

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 105

Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer

Antonelli, A., Bocci, G., La Motta, C., Ferrari, S. M., Fallahi, P., Fioravanti, A., Sartini, S., Minuto, M., Piaggi, S., Corti, A., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism

Thyroid Cancer Diagnosis and TreatmentHeterocyclic Compound Synthesis and Bioactivity

Cited by 66

Use of suramin in treatment of prostatic carcinoma refractory to conventional hormonal manipulation

LaRocca, R. V., Cooper, M. R., Uhrich, M., Danesi, R., Walther, M. M., Linehan, W. M., & Myers, C. E. (1991) · Urologic Clinics of North America

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

Cited by 57

Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine

Bocci, G., Danesi, R., Marangoni, G., Fioravanti, A., Boggi, U., Esposito, I., Fasciani, A., Boschi, E., Campani, D., Bevilacqua, G., et al. (2004) · European Journal of Pharmacology

Angiogenesis and VEGF in CancerPancreatic and Hepatic Oncology Research

Cited by 49

EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan

Loupakis, F., Cremolini, C., Fioravanti, A., Orlandi, P., Salvatore, L., Masi, G., Schirripa, M., Di Desidero, T., Antoniotti, C., Canu, B., et al. (2014) · Targeted Oncology

Colorectal Cancer Treatments and StudiesHER2/EGFR in Cancer Research

Cited by 33